From Financial Modeling Prep: 2025-01-10 16:58:00

UBS analysts reaffirmed a Buy rating on Guardant Health (NASDAQ:GH) with a $40 price target, naming it their top pick in the Life Sciences & Diagnostic Tools sector. The firm cited Guardant’s strong growth potential, particularly driven by the momentum of its Shield test for colorectal cancer screening.

Guardant’s upcoming report on Shield CRC screening volumes is expected to highlight the test’s market potential. A survey of 50 physicians indicated that blood-based CRC screening tests like Shield could capture a 10% market share in 1-2 years, double the current market expectation, suggesting a larger commercial opportunity.

Potential catalysts, such as pricing improvements and updates to medical guidelines, are anticipated to strengthen Shield’s market position. Concerns about competition from Exact Sciences’ upcoming blood-based CRC screening data are seen as overstated by UBS analysts.

In addition to Shield, Guardant’s growth prospects are supported by its Reveal test for minimal residual disease, which is projected to receive expanded Medicare reimbursement by the first half of 2025.



Read more at Financial Modeling Prep:: Guardant Health Named UBS Top Pick Amid Strong Gro…